



Program & Theme

Life Sciences = Future. Jobs. Exports.

As Australia's window of mining-driven prosperity begins to close, and car manufacturing phases out, it is widely acknowledged that building Australia's capacity as a technologically innovative country is vital for our economic future.

The structural transformation of Australia's economy has commenced toward high-tech, knowledge-based industries, which has the capacity to generate a globally-competitive economy, higher exports and sustainable, high-skilled jobs.

Australia has a strong comparative advantage in 'high tech, high cost, low volume' manufacturing to elaborately-transform goods such as medical devices and bio-pharmaceuticals, and a burgeoning biotechnology and life sciences industry that is globally impressive by any comparative measure.

We live in a time where technological innovation, knowledge and networking are the drivers of our productivity, and technology based on the life sciences is an area where Australia has great expertise that could and should be leveraged to our economy's advantage.

The theme of this year's AusBiotech 2014 national conference - Life Sciences = Future. Jobs. Exports - brings our focus to the developments in biotechnology and the life sciences industry that will significantly boost Australia's economic performance and build our nation.

AusBiotech 2014: Wednesday Sessions					
8:00am - 5:00pm	Registration Desk Open				
9:00am - 12:00pm	<p>Griffith University Tour AusBiotech and Griffith University invite conference delegates to take part in an exclusive opportunity to tour two of the Gold Coast and Australia's most innovative health and life science research and teaching centres. Join us on a morning excursion to Griffith University where you have the option of touring either:</p> <p>The Institute for Glycomics: the largest dedicated academic glycoscience unit in Australia with unique co-located facilities covering biology, chemistry and the structural and analytical sciences; or,</p> <p>The Griffith Health Centre: a \$150 million, 10-storey building - Griffith's largest investment in a single building in its 40-year history - accommodating more than 2000 students undertaking everything from medicine to dentistry to physiotherapy, and hosting ground-breaking clinical trial research out of our Griffith Health Institute.</p> <p>Tours to run from 8.45 - 11.45am on Wednesday 29 October 2014 returning in time for the opening plenary session Spaces are limited and you must opt in for this event during the registration process.</p>				
12:00 - 1:00pm	BioIndustry Exhibition Hall Official Opening Luncheon				
1:00 - 2:45pm	<p>Official Opening of AusBiotech 2014 Dr Anna Lavelle, Chief Executive Officer, AusBiotech Hon. Ian Walker MP, Minister for Science, Information Technology, Innovation and the Arts</p> <p>Announcement of the Johnson & Johnson Innovation 2014 Industry Excellence Awards</p> <p>Plenary Session 1 Dr Sue Dillon, Global Therapeutic Area Head for Immunology for Janssen <i>Accessing innovation around the world</i></p> <p>Plenary Session 2 Johnson & Johnson Panel Session Moderator: Dr Anna Lavelle, Chief Executive Officer, AusBiotech Dr Sue Dillon, Global Therapeutic Area Head for Immunology for Janssen Dr Hugh Davis, Vice President, Biologics Clinical Pharmacology in the Biotechnology Center of Excellence of Janssen R&D Dr Patrick Verheyen, Head, Johnson & Johnson Innovation, London Dr Dong Wu, Head, Johnson & Johnson Asia Pacific Innovation Centre</p>				
2:45-3:30pm	Afternoon Tea and Networking with BioIndustry Exhibitors				
	Room 5	Room 6	Room 7	Room 8	
3:30-5:00pm	<p>Investors Unplugged <i>Chair: Lawrence Gozlan, Chief Executive Officer, Scientia Capital</i></p> <p>Brigitte Smith, Managing Director/Portfolio Manager, GBS Venture Partners Pty Ltd</p> <p>Dr Graeme Wald, Investment Director, BioScience Managers</p> <p>Amit Drach, Analyst, Sphera Global Healthcare Fund</p>	<p>Global Regulatory Issues <i>Chair: Bernard O'Shea, Partner Norton Rose Fulbright</i></p> <p>Rick Robinson, Global Head Life Sciences and Healthcare, Norton Rose Fulbright (USA)</p> <p>Dr Chris Holloway, Group Director and CSO, ERA Consulting Group (UK)</p> <p>Deidre Malton, Director, Regulatory Services, Commercial Eyes</p> 	<p>New Economy, new manufacturing <i>Chair: Julie Phillips, Chief Executive Officer, BioDiem</i></p> <p>Prof Dietmar Hutmacher, Professor, Institute of Health & Biomedical Innovation, QUT</p> <p>Dr Sherry Kothari, CEO & Managing Director, CRC for Cell Therapy Manufacturing</p> <p>Prof John Barnes, Research Program Director, High Performance Metals, CSIRO</p>	<p>What does success look like? <i>Chair: Rob McInnes, Partner DibbsBarker</i></p> <p>Neil Abdollahian, Managing Director, Clarity Point Partners</p> <p>Dr Geoff Cumming, Chief Executive Officer, Anteo Diagnostics</p> <p>Dr Phil Kearney, Director Licensing & External Research, Merck Sharp & Dohme</p>	
5:15 - 7:00pm	<p>AusBiotech 2014 National Conference Official Opening Reception in conjunction with Johnson & Johnson Innovation <i>Supported by the Queensland Government</i></p>  				



AusBiotech 2014: Thursday Sessions			
7:30 - 5:00pm	Registration Desk Open		
7:45 - 8:45am	Room 4 AusBiotech Annual General Meeting (45 Minutes) <i>Light breakfast served from 7.45 - 8.00am</i>		
9:00 - 5:00pm	BioIndustry Exhibition and Business Matching Open		
9:00 - 5:00pm	Agriculture & Food Biotechnology Symposium <i>(Please see separate tab for program)</i>		
9:00 - 10:30am	Plenary Session 3 Prof Ian Edvalson , Partner, Wilson Sonsini Goodrich Rosati - <i>The challenges for pharma and biotech in emerging markets - Focus on China and India</i> Plenary Session 4 Millis Oration: Prof Frank Gannon , Director & CEO, QIMR Berghofer Medical Research Institute <i>Supported by CSL</i> <i>The connection between medical research and business</i> 		
10:30 - 11:00am	HealthinSA Morning Tea and Networking with BioIndustry Hall Exhibitors  		
	Room 5	Room 6	Room 7
11:00 - 12:30pm	Translation from innovation to the clinic and beyond <i>Chair: Dr Mark Ashton, Senior Director, Commercial Engagement, Health, UniQuest</i> Dr Dennis Liotta , Executive Director, The Emory Institute for Drug Development, Emory University, Atlanta Prof Darren Kelly , Chief Executive Officer & Director, Fibrotech Therapeutic Mark Smythe , Vice President, Protagonist Dan Baker , Vice President Immunology R&D, Johnson & Johnson Keith Blundy , CEO, Cancer Research Technology	Risks you might overlook <i>Chair: Travis McIntosh, Assistant Vice President, Life Science Specialist, Asia Pacific Zone, Chubb Insurance Company of Australia</i> George Gilmour , Senior Underwriter, Chubb Insurance Company of Australia Shane Aitken , Chief Operating Officer, Avatar Brokers Pty Limited Ashley Collins , Senior Loss Control Engineer, Chubb Insurance Company of Australia 	Focus on China <i>Chair: Glenn Cross, Chief Operating Officer, AusBiotech</i> Prof Ian Edvalson , Partner, Wilson Sonsini Goodrich Rosati Dr Binhui Ni , Head and Senior Director, Partnering and External Innovation, Sanofi A/Prof David Anderson , Deputy Director of the Burnet Institute, and Founder and CEO of Nanjing BioPoint Diagnostic Technology Co. Ltd Dr Darren Xiaohui Ji , Global Head of Asia and Emerging Markets Partnering, F. Hoffmann-La Roche LTD.
12:30 - 1:30pm	Lunch, Networking with BioIndustry Exhibitors & AbbVie Student Poster Awards Judging		
1:30 - 3:00pm	Converging the relationship between industry, investors and academia <i>Chair: Dr Anna Lavelle, Chief Executive Officer, AusBiotech</i> Brigitte Smith , Managing Director/Portfolio Manager, GBS Venture Partners Pty Ltd Dr Dean Moss , Chief Executive Officer, UniQuest Robert Hendriks , Managing Director, Genzyme Dr Chris Smith , Investment Manager, Brandon Capital	De-risking biopharmaceutical product development and manufacturing <i>Chair: David Hughes, Chief Executive Officer, BioPharmaceuticals Australia</i> Marc Goemans , Business Development, Asia-Pacific, Patheon Biologics Pty Ltd Mike Gerometta , Head of CNC Development, Circadian Technologies Limited Maria Halasz , Chief Executive Officer, Cellmid Limited Helen Fisher , Leader - Life Sciences, Deloitte Australia	Clinical Trials – Why Australia? <i>Chair: TBC, INC Research</i> Lisa Nelson , Chief Commercial Officer, Linear Clinical Research Terry Hurst , Chief Executive Officer, Q-Pharm Christina Chen , Managing Director, Tigermed Matthew Palmer , Project Director, INC Research 

			
3:00 - 3:30pm	Afternoon Tea & Networking with BioIndustry Exhibitors		
3:30 - 5:00pm	BioIndustry Hall Trade Afternoon		
	Room 5	Room 6	Room 7
3:30 - 5:00pm	<p>The Changing Face of Big Pharma <i>Chair: Glenn Cross, Chief Operating Officer, AusBiotech</i></p> <p>Kirsten O'Doherty, Chief Executive Officer, AbbVie</p> <p>Dr Donnie McGrath, Vice President, Search & Evaluation, Bristol-Myers Squibb</p> <p>Iain Dukes, Global Lead, Merck</p> <p>Brad Edwards, General Manager Australia & New Zealand, Shire Australia Pty Ltd</p> <p>Dr Terence Porter, Vice President, Search & Evaluation, Takeda Pharmaceutical Company Limited</p> <p>Dr Ajay Gautam, Executive Director & Head, External Collaborations Asia & Emerging Markets, AstraZeneca</p>	<p>Introduction of BioSimilar into Australia <i>Chair: Dr Chris Holloway, Group Director and CSO, ERA Consulting Group (UK)</i></p> <p>Dr Kevin Grant, Office of Laboratory & Scientific Services, Monitoring & Compliance Group, Therapeutic Goods Administration</p> <p>Dr Tony Mulcahy, Director, Site Operations, Hospira</p> <p>Elizabeth de Somer, Director Policy & Advocacy, Medicines Australia</p> <p>Dr Chris Holloway, Group Director and CSO, ERA Consulting Group (UK)</p>	<p>Personalised Medicine <i>Chair: Dr Joy Rathjen, Senior Research Fellow, Menzies Research Institute Tasmania, University of Tasmania</i></p> <p>A/Prof Ernst Wolvetang, Director, Cell Reprogramming Australia and Group Leader, University of Queensland</p> <p>Kyle Kolaja, Vice President of Business Development, Cellular Dynamics International</p> <p>Michelle Burke, Director, External Affairs, Bristol-Myers Squibb (Australia) Pty Ltd</p>
5:00-6:00pm	<p>Networking Hour UKTI Networking Function - UKTI Pavilion <i>(Invitation Only)</i></p> <p></p>		
7:00 - 11:00pm	<p>Patheon and AusBiotech Official Conference Dinner <i>Supported by the Queensland Government</i></p> <p> </p>		

AusBiotech 2014: Friday Sessions			
8:30 - 12:00pm	Registration Desk & BioIndustry and Business Matching Opens		
8:30 - 12:00pm	Agriculture & Food Biotechnology Symposium (<i>Please see separate tab for program</i>)		
8:45 - 9:05am	Plenary Session 5 Improving the Australian clinical trials environment Dr Timothy Dyke , Executive Director, Strategic Policy Group, National Health & Medical Research Council		
9:05 - 9:30am	Plenary Session 6 Bench marking Biotech: Initiatives for the development of the biotechnology sector in Asia Pacific and their impact: Rhenu Bhuller , Senior Vice President, Healthcare, Frost & Sullivan <i>Printed reports will be distributed during the address</i>		
9:30 - 10:00am	Morning Tea and Networking with BioIndustry Exhibitors		
	Room 5	Room 6	Room 7
10:00 - 11:00am	<p>The Third 'R'... Reimbursement <i>Chair: Michelle Burke, Director, External Affairs, Bristol-Myers Squibb (Australia) Pty Ltd</i></p> <p>Natasha Doherty, Associate Director, Health Economics & Social Policy, Corporate Finance, Deloitte</p> <p>Richard Bartlett, First Assistant Secretary of Medical Benefits Division, Department of Health</p>	<p>What are we doing for commercialisation in Australia? <i>Chair: Karen Stein, R&D Tax Partner, Deloitte</i></p> <p>Doron Ben-Meir, Chief Executive Officer, Commercialisation Australia</p> <p>Barry Thomas, VP, Director Asia Pacific - Cook Medical, Cook Australia Pty Ltd</p> <p>Helen Fisher, Leader - Life Sciences, Deloitte Australia</p> <p style="text-align: center;">Deloitte.</p>	<p>Public Forum: "Perspectives on dementia and Alzheimer's and biotechnology's role in treatments and prevention"</p> <p>9.45am: Arrival and registration 10.00 - 11.00am: Public Forum Session 11.00am - 12.00pm: Opportunity to view the conference exhibition</p> <p><i>Chair: Prof Ralph Martins AO, Director of the Centre of Excellence for Alzheimer's Disease Research & Care at Edith Cowan University</i></p> <p>Medical Research Perspective Prof Pankaj Sah, Deputy Director (Research) at The Queensland Brain Institute (QBI). Prof Ira Shoulson, Neurology, Pharmacology and Human Services, Georgetown University, Washington DC and Non-executive Director, Prana Biotechnology</p> <p>Patient and family perspective Victoria Beedle, Chief Executive Officer of Alzheimer's Australia Sanjeeta Mackrani is the Business Development Manager at Alzheimer's Queensland</p> <p>A biotech perspective Dr Peter French, Chief Executive Officer, Benitec Biopharma</p> <p>Separate registration: Click here</p>
11:00am - 11:10am	Room Change to Plenary Hall		
11:10 - 11:40pm	AusBiotech Advocacy Policy and Strategic Plan Update: Dr Deborah Rathjen , CEO, Bionomics		
11:40 - 12:15pm	AbbVie Student Award Winner Announced and AusBiotech 2014 National Conference Closing Reception		
12.15 - 12.45pm	AusBiotech 2014 Closing Networking Lunch		
	Flight times Gold Coast to Melbourne 1.50pm – 5.10pm 2.00pm – 5.15pm 2.05pm – 6.50pm 5.15pm – 8.35pm	Flight times Gold Coast to Sydney 2.05pm – 4.35pm 2.45pm – 5.10pm 4.05pm – 6.35pm 4.40pm – 7.10pm	

2014 Event Information

Tuesday 28 October Exhibitor registration opens, Exhibitor bump-in.

Wednesday 29 October Conference program Day 1, BioIndustry exhibition opening luncheon, Official conference opening, BioIndustry exhibition & Business Matching, AusBiotech official welcome reception.

- Thursday 30** Conference program Day 2, BioIndustry exhibition & Business Matching, Trade Afternoon in the BioIndustry exhibition, Ag & Food
October Biotechnology Symposium, AusBiotech official conference dinner.
- Friday 31 October** Conference program Day 3, BioIndustry exhibition & Business Matching, Ag & Food Biotechnology Symposium, AusBiotech official closing
reception.